Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
   
Ask the Experts About

Managing Side Effects of HIV TreatmentManaging Side Effects of HIV Treatment
          
Rollover images to visit our other forums!
Recent AnswersAsk a Question
  
  • Email Email
  • Glossary Glossary


R278474
Jan 12, 2005

What do you know about R278474?

Has it been presented at any conferences? Why has the media made such a big deal about it?

Response from Dr. Conway

The quest is on for drugs that will be effective against HIV and to which it will be difficult for the virus to become resistant. Two drugs of this category are the NNRTIs TMC120 and TMC125, NNRTIs currently in clinical trials. R278474 (developed at Rutgers University) is yet another drug that may represent progress over the "TMC" in that the virus may have even more difficulty in developing resitance to it, as the drug could still attach to virus that has the usual NNRTI resistance mutations. It seems to be absorbed orally and I understand that clinical trials are planned, although I am not yet aware of any results.



Previous
Intolerable sides effects
Next
indinavir stones

  
  • Email Email
  • Glossary Glossary

 Get Email Notifications When This Forum Updates or Subscribe With RSS


 
Advertisement



Q&A TERMS OF USE

This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.

Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.

Review our complete terms of use and copyright notice.

Powered by ExpertViewpoint

Advertisement